to Lectin Pathway Activation and -2: Significant Contribution of MASP-1 Lectin-Associated Serine Protease (MASP)-1 Peptides against Mannose-Binding Complement with Phage Display Selected Selective Inhibition of the Lectin Pathway of
暂无分享,去创建一个
[1] K. Skjødt,et al. MBL-associated serine protease-3 circulates in high serum concentrations predominantly in complex with Ficolin-3 and regulates Ficolin-3 mediated complement activation. , 2010, Immunobiology.
[2] A. Sahu,et al. Identification of Complin, a Novel Complement Inhibitor that Targets Complement Proteins Factor B and C2 , 2010, The Journal of Immunology.
[3] A. Krarup,et al. Activation of mannan‐binding lectin‐associated serine proteases leads to generation of a fibrin clot , 2010, Immunology.
[4] K. Skjødt,et al. A Novel Mannose-binding Lectin/Ficolin-associated Protein Is Highly Expressed in Heart and Skeletal Muscle Tissues and Inhibits Complement Activation* , 2010, The Journal of Biological Chemistry.
[5] M. Frank,et al. Therapeutic potential of complement modulation , 2010, Nature Reviews Drug Discovery.
[6] R. Wallis,et al. Paths reunited: Initiation of the classical and lectin pathways of complement activation. , 2010, Immunobiology.
[7] John D Lambris,et al. Recent developments in low molecular weight complement inhibitors. , 2009, Molecular immunology.
[8] S. Thiel,et al. MAp44, a Human Protein Associated with Pattern Recognition Molecules of the Complement System and Regulating the Lectin Pathway of Complement Activation1 , 2009, The Journal of Immunology.
[9] P. Gál,et al. Early complement proteases: C1r, C1s and MASPs. A structural insight into activation and functions. , 2009, Molecular immunology.
[10] P. Gál,et al. Complement protease MASP-1 activates human endothelial cells: PAR4 activation is a link between complement and endothelial function , 2009 .
[11] P. Garred,et al. MBL2, FCN1, FCN2 and FCN3-The genes behind the initiation of the lectin pathway of complement. , 2009, Molecular immunology.
[12] P. Gál,et al. MASP-1, a Promiscuous Complement Protease: Structure of Its Catalytic Region Reveals the Basis of Its Broad Specificity1 , 2009, The Journal of Immunology.
[13] P. Gál,et al. C1, MBL-MASPs and C1-inhibitor: novel approaches for targeting complement-mediated inflammation. , 2008, Trends in molecular medicine.
[14] A. Krarup,et al. The action of MBL-associated serine protease 1 (MASP1) on factor XIII and fibrinogen. , 2008, Biochimica et biophysica acta.
[15] K. Werdan,et al. Serine Protease Inhibitor Nafamostat Given Before Reperfusion Reduces Inflammatory Myocardial Injury by Complement and Neutrophil Inhibition , 2008, Journal of cardiovascular pharmacology.
[16] A. Jaśkiewicz,et al. Peptomeric analogues of trypsin inhibitor SFTI-1 isolated from sunflower seeds. , 2008, Bioorganic & medicinal chemistry.
[17] Shigeto Miura,et al. Mannose-Binding Lectin (MBL)-Associated Serine Protease (MASP)-1 Contributes to Activation of the Lectin Complement Pathway , 2008 .
[18] John D. Lambris,et al. The Classical Complement Cascade Mediates CNS Synapse Elimination , 2007, Cell.
[19] John D Lambris,et al. Complement-targeted therapeutics , 2007, Nature Biotechnology.
[20] S. Thiel. Complement activating soluble pattern recognition molecules with collagen-like regions, mannan-binding lectin, ficolins and associated proteins. , 2007, Molecular immunology.
[21] D. Hourcade,et al. Properdin Can Initiate Complement Activation by Binding Specific Target Surfaces and Providing a Platform for De Novo Convertase Assembly1 , 2007, The Journal of Immunology.
[22] L. Gráf,et al. When the surface tells what lies beneath: combinatorial phage-display mutagenesis reveals complex networks of surface-core interactions in the pacifastin protease inhibitor family. , 2007, Journal of molecular biology.
[23] P. Gál,et al. Serine proteases of the classical and lectin pathways: similarities and differences. , 2007, Immunobiology.
[24] S. Thiel,et al. Cooperation between MASP-1 and MASP-2 in the generation of C3 convertase through the MBL pathway. , 2006, International immunology.
[25] John D Lambris,et al. Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. , 2006, Journal of medicinal chemistry.
[26] D. Craik,et al. Discovery, Structural Determination, and Putative Processing of the Precursor Protein That Produces the Cyclic Trypsin Inhibitor Sunflower Trypsin Inhibitor 1* , 2005, Journal of Biological Chemistry.
[27] A. Sjöholm,et al. Functional analysis of the classical, alternative, and MBL pathways of the complement system: standardization and validation of a simple ELISA. , 2005, Journal of immunological methods.
[28] G. Ambrus,et al. The structure of MBL-associated serine protease-2 reveals that identical substrate specificities of C1s and MASP-2 are realized through different sets of enzyme-substrate interactions. , 2004, Journal of molecular biology.
[29] G. Crooks,et al. WebLogo: a sequence logo generator. , 2004, Genome research.
[30] K. Hajela,et al. Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. , 2004, Molecular immunology.
[31] R. Leatherbarrow,et al. The conserved P1' Ser of Bowman-Birk-type proteinase inhibitors is not essential for the integrity of the reactive site loop. , 2003, Biochemical and biophysical research communications.
[32] D. Craik,et al. Enzymatic Cyclization of a Potent Bowman-Birk Protease Inhibitor, Sunflower Trypsin Inhibitor-1, and Solution Structure of an Acyclic Precursor Peptide* , 2003, Journal of Biological Chemistry.
[33] R. Leatherbarrow,et al. The Structural Basis of a Conserved P2 Threonine in Canonical Serine Proteinase Inhibitors , 2003, Journal of biomolecular structure & dynamics.
[34] L. Gráf,et al. Natural Substrates and Inhibitors of Mannan-Binding Lectin-Associated Serine Protease-1 and -2: A Study on Recombinant Catalytic Fragments 1 , 2003, The Journal of Immunology.
[35] W. Grabarse,et al. Monomeric structures of the zymogen and active catalytic domain of complement protease c1r: further insights into the c1 activation mechanism. , 2002, Structure.
[36] John D Lambris,et al. Complement: more than a 'guard' against invading pathogens? , 2002, Trends in immunology.
[37] Robert M Cooke,et al. A conserved cis peptide bond is necessary for the activity of Bowman-Birk inhibitor protein. , 2002, Biochemistry.
[38] A. Jaśkiewicz,et al. Chemical synthesis and kinetic study of the smallest naturally occurring trypsin inhibitor SFTI-1 isolated from sunflower seeds and its analogues. , 2002, Biochemical and biophysical research communications.
[39] K. Hajela,et al. The biological functions of MBL-associated serine proteases (MASPs). , 2002, Immunobiology.
[40] R. Leatherbarrow,et al. Peptide mimics of the Bowman-Birk inhibitor reactive site loop. , 2002, Biopolymers.
[41] J. Drijfhout,et al. Specific Inhibition of the Classical Complement Pathway by C1q-Binding Peptides1 , 2001, The Journal of Immunology.
[42] J. Jensenius,et al. Substrate Specificities of Recombinant Mannan-binding Lectin-associated Serine Proteases-1 and -2* , 2001, The Journal of Biological Chemistry.
[43] D. Craik,et al. Solution structures by 1H NMR of the novel cyclic trypsin inhibitor SFTI-1 from sunflower seeds and an acyclic permutant. , 2001, Journal of molecular biology.
[44] R. Wallis,et al. Stoichiometry of Complexes between Mannose-binding Protein and Its Associated Serine Proteases , 2001, The Journal of Biological Chemistry.
[45] M. Walport. Complement. First of two parts. , 2001, The New England journal of medicine.
[46] Michael C. Montalto,et al. A Keratin Peptide Inhibits Mannose-Binding Lectin1 , 2001, The Journal of Immunology.
[47] S. Thiel,et al. Proteolytic Activities of Two Types of Mannose-Binding Lectin-Associated Serine Protease , 2000, The Journal of Immunology.
[48] Dimitrios Morikis,et al. Binding Kinetics, Structure-Activity Relationship, and Biotransformation of the Complement Inhibitor Compstatin1 , 2000, The Journal of Immunology.
[49] G. Arlaud,et al. Crystal structure of the catalytic domain of human complement C1s: a serine protease with a handle , 2000, The EMBO journal.
[50] S. Sidhu,et al. Phage display for selection of novel binding peptides. , 2000, Methods in enzymology.
[51] S Luckett,et al. High-resolution structure of a potent, cyclic proteinase inhibitor from sunflower seeds. , 1999, Journal of molecular biology.
[52] R. Leatherbarrow,et al. The role of the P2' position of Bowman-Birk proteinase inhibitor in the inhibition of trypsin. Studies on P2' variation in cyclic peptides encompassing the reactive site loop. , 1999, Biochimica et biophysica acta.
[53] R. Leatherbarrow,et al. The role of threonine in the P2 position of Bowman-Birk proteinase inhibitors: studies on P2 variation in cyclic peptides encompassing the reactive site loop. , 1998, Journal of molecular biology.
[54] S. Philipp,et al. Mutational analysis of disulfide bonds in the trypsin-reactive subdomain of a Bowman-Birk-type inhibitor of trypsin and chymotrypsin--cooperative versus autonomous refolding of subdomains. , 1998, European journal of biochemistry.
[55] John D Lambris,et al. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. , 1996, Journal of immunology.
[56] G. Fields,et al. Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. , 2009, International journal of peptide and protein research.
[57] G. P. Smith,et al. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. , 1985, Science.
[58] M. Laskowski,et al. Thermodynamics and kinetics of single residue replacements in avian ovomucoid third domains: effect on inhibitor interactions with serine proteinases. , 1982, Biochemistry.
[59] A. Berger,et al. On the size of the active site in proteases. I. Papain. , 1967, Biochemical and biophysical research communications.